Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Prothena Corporation plc - Ordinary Shares (NQ:PRTA)

9.930 -0.250 (-2.46%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Prothena Corporation plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Prothena Reports Fourth Quarter and Full Year 2022 Financial Results, and Provides Financial Guidance and Business Highlights
From Prothena Corporation plc
Via Business Wire
News headline image
Earnings Outlook For Prothena Corp ↗
 
Via Benzinga
News headline image
Prothena to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
From Prothena Corporation plc
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Prothena Touts Encouraging Data From Early-Stage Alzheimer's Candidate ↗
 
Via Benzinga
News headline image
Analyst Expectations for Prothena Corp's Future ↗
 
Via Benzinga
Cantor Fitzgerald Maintains Overweight Rating for Prothena Corp: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
What 4 Analyst Ratings Have To Say About Prothena Corp ↗
Within the last quarter, Prothena Corp (NASDAQ:PRTA) has observed the following analyst ratings: 
Via Benzinga
News headline image
Earnings Scheduled For February 23, 2023 ↗
Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter. 
Via Benzinga
News headline image
Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Reports Topline Phase 1 Single Ascending Dose Study Results of PRX005, a Novel Anti-MTBR-Tau Antibody for the Potential Treatment of Alzheimer’s Disease
From Prothena Corporation plc
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For January 27, 2023 ↗
 
Via Benzinga
News headline image
Biotech Bonanza: 2023 Biotech Outlook As The Fed Remains Hawkish ↗
2023 can be the year of biotechs after two consecutive years of negative or barely positive returns. 
Via Talk Markets
News headline image
How To Weather These Choppy Markets ↗
Until we get an absolute bottom in the markets, the best way to avoid experiencing a devastating permanent loss of capital is to keep away from stocks with deteriorating fundamentals and heavy insider... 
Via Talk Markets
News headline image
Top Biotech Companies Are Making Steady Progress In Developing Treatments To Fight Alzheimer’s Disease ↗
The estimated cost of Alzheimer's disease and related dementia (ADRD) care in 2021 was $355 billion. Investing in the top companies that are making steady progress toward developing a treatment for... 
Via Talk Markets
News headline image
Prothena Announces Pricing of Public Offering of 3,250,000 Ordinary Shares
From Prothena Corporation plc
Via Business Wire
News headline image
Recap: Prothena Corp Q3 Earnings ↗
Prothena Corp (NASDAQ:PRTA) reported its Q3 earnings results on Thursday, November 3, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Why Prothena Shares Are Trading Lower ↗
Prothena Corporation PLC (NASDAQ: PRTA) shares are trading lower by 6.53% to $59.10 during Wednesday morning. The company announced that it has commenced an underwritten public offering of 3,000,000 of... 
Via Benzinga
News headline image
Why Prothena Shares Are Nosediving During Tuesday's After-Hours Session ↗
Prothena Corporation PLC (NASDAQ: PRTA) shares are trading lower by some 8.35% to $57.95 during Tuesday's after-hours session. The company announced that it has commenced an underwritten public... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Prothena Announces Proposed Public Offering of Ordinary Shares
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Presents Data Demonstrating Consistent Survival Benefit Observed with Birtamimab in Mayo Stage IV AL Amyloidosis Patients in Phase 3 VITAL Study at ASH 2022
From Prothena Corporation plc
Via Business Wire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
News headline image
Prothena Announces Achievement of $40 Million Clinical Milestone Payment from Novo Nordisk for PRX004/NNC6019 Under Investigation for the Treatment of ATTR Cardiomyopathy
From Prothena Corporation plc
Via Business Wire
News headline image
Roche's Alzheimer's Drug Fails In Phase 3; Here's The Fallout For Biogen, Lilly, Prothena And Others ↗
Biogen rose on Roche's Alzheimer's failure as a potential competitor drops off the map. 
Via Investor's Business Daily
News headline image
Prothena Reports Third Quarter 2022 Financial Results and Business Highlights
From Prothena Corporation plc
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For November 4, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Prothena to Present Data on Survival Benefit Observed in Completed Phase 3 Study of Drug Candidate Birtamimab in Patients with Mayo Stage IV AL Amyloidosis at the ASH 2022 Meeting
From Prothena Corporation plc
Via Business Wire
News headline image
Earnings Preview: Prothena Corp ↗
Prothena Corp (NASDAQ:PRTA) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that Prothena Corp... 
Via Benzinga
News headline image
As Small Caps Rally, These 3 Finance High-Yielders Could Have Further Upside ↗
In the past month with the Russell 2000 index up roughly 7%, as compared to the S&P 500 index up nearly 4.8%, it is evident that small cap stocks are leading the charge in this bear market rally. The... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.